WO2001075049A2 - Nouveau polypeptide, chaine legere de clathrine humaine 11, et polynucleotide codant pour ce polypeptide - Google Patents
Nouveau polypeptide, chaine legere de clathrine humaine 11, et polynucleotide codant pour ce polypeptide Download PDFInfo
- Publication number
- WO2001075049A2 WO2001075049A2 PCT/CN2001/000490 CN0100490W WO0175049A2 WO 2001075049 A2 WO2001075049 A2 WO 2001075049A2 CN 0100490 W CN0100490 W CN 0100490W WO 0175049 A2 WO0175049 A2 WO 0175049A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- polynucleotide
- light chain
- clathrin light
- human clathrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Definitions
- clathrin tripods self-assemble to form a closed polyhedral structure known as a "cage."
- clathrin's polyhedral assembly forms a coating cavity that increases in the curved portion by swallowing extracellular environment-derived substances.
- Another object of the present invention is to provide a method for diagnosing and treating a disease associated with an abnormality of human clathrin light chain 11.
- the invention also relates to a method for screening compounds that mimic, activate, antagonize or inhibit the activity of human clathrin light chain 11 protein, which comprises utilizing the polypeptide of the invention.
- the invention also relates to compounds obtained by this method.
- coli Streptomyces
- bacterial cells such as Salmonella typhimurium
- fungal cells such as yeast
- plant cells such as fly S2 or Sf9
- animal cells such as CH0, COS or Bowes melanoma cells.
- Transformation of a host cell with a DNA sequence described in the present invention or a recombinant vector containing the DNA sequence can be performed using conventional techniques well known to those skilled in the art.
- the host is a prokaryote, such as E. coli
- competent cells capable of absorbing DNA can be harvested after the exponential growth phase and treated with the CaCl 2 method. The steps used are well known in the art. Alternatively, MgCl 2 is used. If necessary, transformation can also be performed by electroporation.
- the host is a eukaryotic organism, the following DNA transfection methods can be used: calcium phosphate co-precipitation method, or conventional mechanical methods such as microinjection, electroporation, and liposome packaging.
- the medium used in the culture may be selected from various conventional mediums. Culture is performed under conditions suitable for host cell growth. After the host cells have grown to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
- a suitable method such as temperature conversion or chemical induction
- Antibodies can also be used to design immunotoxins that target a particular part of the body.
- Human clathrin light chain Human clathrin light chain
- the polynucleotide encoding human clathrin light chain 11 can also be used for a variety of therapeutic purposes. Gene therapy technology can be used to treat abnormal cell proliferation, development, or metabolism caused by the non-expression or abnormal / inactive expression of human clathrin light chain 11.
- Recombinant gene therapy vectors (such as viral vectors) can be designed to express mutated human clathrin light chain 11 to inhibit endogenous human clathrin light chain 11 activity.
- a mutated human clathrin light chain 11 may be a shortened human clathrin light chain 11 lacking a signaling domain, and although it can bind to a downstream substrate, it lacks signaling activity.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne un nouveau polypeptide, une chaîne légère de clathrine humaine 11, et un polynucléotide codant pour ce polypeptide ainsi qu'un procédé d'obtention de ce polypeptide par des techniques recombinantes d'ADN. L'invention concerne en outre les applications de ce polypeptide dans le traitement de maladies, notamment des tumeurs malignes, de l'hémopathie, de l'infection par VIH, de maladies immunitaires et de diverses inflammations. L'invention concerne aussi l'antagoniste agissant contre le polypeptide et son action thérapeutique ainsi que les applications de ce polynucléotide codant pour la chaîne légère de clathrine humaine 11.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU63723/01A AU6372301A (en) | 2000-03-27 | 2001-03-26 | A novel polypeptide, human light-chain clathrine 11 and the polynucleotide encoding the polypeptide |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00115179 CN1315390A (zh) | 2000-03-27 | 2000-03-27 | 一种新的多肽——人网格蛋白轻链11和编码这种多肽的多核苷酸 |
| CN00115179.7 | 2000-03-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2001075049A2 true WO2001075049A2 (fr) | 2001-10-11 |
| WO2001075049A3 WO2001075049A3 (fr) | 2004-04-15 |
Family
ID=4584648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2001/000490 Ceased WO2001075049A2 (fr) | 2000-03-27 | 2001-03-26 | Nouveau polypeptide, chaine legere de clathrine humaine 11, et polynucleotide codant pour ce polypeptide |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1315390A (fr) |
| AU (1) | AU6372301A (fr) |
| WO (1) | WO2001075049A2 (fr) |
-
2000
- 2000-03-27 CN CN 00115179 patent/CN1315390A/zh active Pending
-
2001
- 2001-03-26 WO PCT/CN2001/000490 patent/WO2001075049A2/fr not_active Ceased
- 2001-03-26 AU AU63723/01A patent/AU6372301A/en not_active Abandoned
Non-Patent Citations (4)
| Title |
|---|
| DATABASE GENBANK [Online] 15 April 1994 SINNETT D. ET AL. Retrieved from embl Database accession no. (M87914) * |
| DATABASE GENBANK [Online] 22 February 2000 ISOGAI ET AL Retrieved from EMBL Database accession no. (AK001656) * |
| JACKSON A. P. ET AL. NATURE vol. 326, no. 6109, 12 March 1987 - 18 March 1987, pages 154 - 159 * |
| UNGEWICKELL E. EMBO J. vol. 2, no. 8, 1993, pages 1401 - 1408 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU6372301A (en) | 2001-10-15 |
| WO2001075049A3 (fr) | 2004-04-15 |
| CN1315390A (zh) | 2001-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2001075103A1 (fr) | Nouveau polypeptide, proteine humaine 9 de toxine de scorpion a chaine courte, et polynucleotide codant pour ce polypeptide | |
| WO2001075049A2 (fr) | Nouveau polypeptide, chaine legere de clathrine humaine 11, et polynucleotide codant pour ce polypeptide | |
| WO2001070966A1 (fr) | Nouveau polypeptide, chaine legere de clathrine humaine 11, et polynucleotide codant pour ce polypeptide | |
| WO2001087954A1 (fr) | Nouveau polypeptide, chaine legere de clathrine humaine 9, et polynucleotide codant ce polypeptide | |
| WO2001075006A2 (fr) | Nouveau polypeptide, chaîne légere de protéine réseau 37, et polynucléotide codant pour ce polypeptide | |
| WO2001072801A1 (fr) | Nouveau polypeptide, proteine ribosomale humaine s11 12, et polynucleotide codant pour ce polypeptide | |
| WO2001064721A1 (fr) | Nouveau polypeptide, adenosine triphosphatase 30, et polynucleotide codant pour ce polypeptide | |
| WO2001079432A2 (fr) | Nouveau polypeptide, facteur humain de transcription de la differentiation cellulaire 58, et polynucleotide codant pour ce polypeptide | |
| WO2001049727A1 (fr) | Nouveau polypeptide, transducteur de signal 9 a effet chemotactique de bacteries, et polynucleotide codant pour ce polypeptide | |
| WO2001072807A1 (fr) | Nouveau polypeptide, neuropeptide humain 11, et polynucleotide codant pour ce polypeptide | |
| WO2001081395A1 (fr) | Nouveau polypeptide, adn topo-isomerase i-15, et polynucleotide codant pour ce polypeptide | |
| WO2001068687A1 (fr) | Nouveau polypeptide, chaine legere de proteine reseau 21, et polynucleotide codant pour ce polypeptide | |
| WO2001066590A1 (fr) | Nouveau polypeptide, chaine legere 14 de clathrine humaine, et polynucleotide codant pour ce polypeptide | |
| WO2001075045A2 (fr) | Nouveau polypeptide, chaine legere de clathrine humaine 17, et polynucleotide codant pour ce polypeptide | |
| WO2001075056A2 (fr) | Nouveau polypeptide, clathrine humaine a chaine legere 20, et polynucleotide codant pour ce polypeptide | |
| WO2001049730A1 (fr) | Nouveau polypeptide, clathrine a chaine legere 12, et polynucleotide codant pour ce polypeptide | |
| WO2001079491A1 (fr) | Nouveau polypeptide, canal ionique humain 12 pour le chlore, et polynucleotide codant pour ce polypeptide | |
| WO2001083728A1 (fr) | Nouveau polypeptide, proteine humaine de transport d'acides amines excitateurs 9, et polynucleotide codant pour ce polypeptide | |
| WO2001074886A1 (fr) | Nouveau polypeptide, glycoproteine amyloidogenique humaine 9, et polynucleotide codant pour ce polypeptide | |
| WO2001068877A1 (fr) | Nouveau polypeptide, proteine humaine de transport 10 d'acides amines excitateurs, et polynucleotide codant pour ce polypeptide | |
| WO2001075037A2 (fr) | Nouveau polypeptide, dihydroorotase humaine 40, et polynucleotide codant pour ce polypeptide | |
| WO2001079431A2 (fr) | Nouveau polypeptide, proteine humaine d'interaction 15 avec la proteine huntingtine, et polynucleotide codant pour ce polypeptide | |
| WO2001064916A1 (fr) | Nouveau polypeptide, proteine humaine de transport d'acides amines excitateurs 9, et polynucleotide codant pour ce polypeptide | |
| WO2001074877A1 (fr) | Nouveau polypeptide, proteine humaine de transport 12 d'acides amines excitateurs, et polynucleotide codant pour ce polypeptide | |
| WO2001066576A1 (fr) | Nouveau polypeptide, glycoproteine amyloidogenique humaine 11, et polynucleotide codant pour ce polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase in: |
Ref country code: JP |